Alimera Sciences Shares Slide on Merger Lawsuit

Dow Jones

2024/09/10

By Michael Susin

Alimera Sciences shares fell on Tuesday after the company said it filed a lawsuit demanding ANI Pharmaceuticals to complete their merger agreement.

Shares were down 20% to $4.40. However, shares have nearly doubled over the last three months.

The pharmaceutical company said it has filed the lawsuit in the Delaware Court of Chancery asking to require ANI Pharmaceuticals to close the merger agreement.

The company said the Alimera shareholders' approval of the deal on Sept. 4 was the last requirement for completing the merger.

ANI Pharmaceuticals wasn't immediately available to provide comments for Dow Jones Newswires.

On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 prior to the announcement. ANI would also repay $72.5 million of Alimera debt.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

September 10, 2024 10:02 ET (14:02 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2466456257"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466456257\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466456257?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466456257","market":"hk","top_or_hot":-1,"title":"Alimera Sciences Shares Slide on Merger Lawsuit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ALIM\">Alimera Sciences</a> shares fell on Tuesday after the company said it filed a lawsuit demanding ANI Pharmaceuticals to complete their merger agreement. \n</p>\n<p>\n  Shares were down 20% to $4.40. However, shares have nearly doubled over the last three months. \n</p>\n<p>\n  The pharmaceutical company said it has filed the lawsuit in the Delaware Court of Chancery asking to require ANI Pharmaceuticals to close the merger agreement. \n</p>\n<p>\n  The company said the Alimera shareholders' approval of the deal on Sept. 4 was the last requirement for completing the merger. \n</p>\n<p>\n  ANI Pharmaceuticals wasn't immediately available to provide comments for Dow Jones Newswires. \n</p>\n<p>\n  On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 prior to the announcement. ANI would also repay $72.5 million of Alimera debt. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2024 10:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alimera Sciences Shares Slide on Merger Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlimera Sciences Shares Slide on Merger Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-10 22:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ALIM\">Alimera Sciences</a> shares fell on Tuesday after the company said it filed a lawsuit demanding ANI Pharmaceuticals to complete their merger agreement. \n</p>\n<p>\n  Shares were down 20% to $4.40. However, shares have nearly doubled over the last three months. \n</p>\n<p>\n  The pharmaceutical company said it has filed the lawsuit in the Delaware Court of Chancery asking to require ANI Pharmaceuticals to close the merger agreement. \n</p>\n<p>\n  The company said the Alimera shareholders' approval of the deal on Sept. 4 was the last requirement for completing the merger. \n</p>\n<p>\n  ANI Pharmaceuticals wasn't immediately available to provide comments for Dow Jones Newswires. \n</p>\n<p>\n  On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 prior to the announcement. ANI would also repay $72.5 million of Alimera debt. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2024 10:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2466456257","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466456257","pubTimestamp":1725976920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alimera Sciences shares fell on Tuesday after the company said it filed a lawsuit demanding ANI Pharmaceuticals to complete their merger agreement.Shares were down 20% to $4.40. However, shares have nearly doubled over the last three months.The pharmaceutical company said it has filed the lawsuit in the Delaware Court of Chancery asking to require ANI Pharmaceuticals to close the merger agreement.The company said the Alimera shareholders' approval of the deal on Sept. 4 was the last requirement for completing the merger.ANI Pharmaceuticals wasn't immediately available to provide comments for Dow Jones Newswires.On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 prior to the announcement. ANI would also repay $72.5 million of Alimera debt.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Alimera Sciences股价因合并诉讼而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALIM":1,"ANIP":0.9},"content_text":"By Michael Susin \n\n\n \n\n\nAlimera Sciences shares fell on Tuesday after the company said it filed a lawsuit demanding ANI Pharmaceuticals to complete their merger agreement. \n\n\n  Shares were down 20% to $4.40. However, shares have nearly doubled over the last three months. \n\n\n  The pharmaceutical company said it has filed the lawsuit in the Delaware Court of Chancery asking to require ANI Pharmaceuticals to close the merger agreement. \n\n\n  The company said the Alimera shareholders' approval of the deal on Sept. 4 was the last requirement for completing the merger. \n\n\n  ANI Pharmaceuticals wasn't immediately available to provide comments for Dow Jones Newswires. \n\n\n  On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 prior to the announcement. ANI would also repay $72.5 million of Alimera debt. \n\n\n \n\n\n  Write to Michael Susin at michael.susin@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2024 10:02 ET (14:02 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}